Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase Ⅲ study conducted by the Hellenic Copperative Oncology Group950106
| Phase Ⅲ trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer |
| Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer |
| Adjuvant Docetaxel for Node-Positive Breast Cancer |
| Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial |
